Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 40-46

  Ghoreschi, Kamran ^a   Thomas, Peter ^a   Breit, Susanne ^a   Dugas, Martin ^b   Mailhammer, Reinhard ^c   Van Eden, Willem ^f   Van der Zee, Ruurd ^f   Biedermann, Tilo ^a   Prinz, Jörg ^a   Mack, Matthias ^b   Mrowietz, Ulrich ^d   Christophers, Enno ^d   Schlöndorff, Detlef ^b   Plewig, Gerd ^a   Sander, Christian A ^a   Rocken, Martin ^a,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INTERLEUKIN 19; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; PERIPHERAL EDEMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SCORING SYSTEM; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-18; INTERLEUKIN-4; INTERLEUKINS; MALE; MIDDLE AGED; PHENOTYPE; PSORIASIS; RECEPTORS, CCR5; SEVERITY OF ILLNESS INDEX; SKIN; TH1 CELLS; TH2 CELLS;

ANIMALIA;

EID: 0037234390     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm804     Document Type: Article

References (46)

1. Christophers, E. & Mrowietz, U. Psoriasis. in Dermatology in General Medicine edn. 5 (eds. Fitzpatrick, T.B., Eisen, A.Z. & Freedberg, I.M.) 495-521 (McGraw-Hill, New York, 1999).
2. Krueger, G. et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137, 280-284 (2001).
3. Prinz, J.C. et al. Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur. J. Immunol. 29, 3360-3368 (1999).
4. Austin, L.M., Ozawa, M., Kikuchi, T., Walters, I.B. & Krueger, J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113, 752-759 (1999).
5. Robert, C. & Kupper, T.S. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341, 1817-1828 (1999).
6. Nestle, F.O., Turka, L.A. & Nickoloff, B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94, 202-209 (1994).
7. + T cells induces psoriasis. Am. J. Pathol. 155, 145-158 (1999).
8. Lebwohl, M. et al. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J. Am. Acad. Dermatol. 39, 464-475 (1998).
9. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch. Dermatol. 132, 419-423 (1996).
10. Abrams, J.R. et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4lg) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192, 681-694 (2000).
11. Gottlieb, S.L. et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1, 442-447 (1995).
12. Ellis, C.N. & Krueger, G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345, 248-255 (2001).
13. Reich, K. et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J. Invest. Dermatol. 116, 319-329 (2001).
14. Asadullah, K. et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: Histologic, immunohistologic, and molecular biology findings. J. Invest. Dermatol. 116, 721-727 (2001).
15. Moore, K.W., de Waal Malefyt, R., Coffman, R.L. & O'Garra, A. interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
16. Trepicchio, W.L. et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest 104, 1527-1537 (1999).
17. Chaudhari, U. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 357, 1842-1847 (2001).
18. Granstein, R.D. New treatments for psoriasis. N. Engl. J. Med. 345, 284-287 (2001).
19. Kamradt, T. & Mitchison, N.A. Tolerance and autoimmunity. N. Engl. J. Med. 344, 655-664 (2001).
20. Rocken, M., Racke, M. & Shevach, E.M. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 17, 225-231 (1996).
21. Biedermann, T. et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur. J. Immunol. 31, 1582-1591 (2001).
22. Abbas, A.K., Murphy, K.M. & Sher, A. Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
23. Paul, W.E. & Seder, R.A. Lymphocyte responses and cytokines. Cell 76, 241-251 (1994).
24. Rocken, M., Urban, J. & Shevach, E.M. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J. Exp. Med. 179, 1885-1893 (1994).
25. Biedermann, T. et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nature Immunol. 11, 1054-1060 (2001).
26. Romagnani, S. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12, 227-257 (1994).
27. Wong, H.L., Costa, G.L., Lotze, M.T. & Wahl, S.M. Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J. Exp. Med. 177, 775-781 (1993).
28. Whitehead, R.P. et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: A Southwest Oncology Group study. J. Immunother. 21, 440-446 (1998).
29. Vokes, E.E., Figlin, R., Hochster, H., Lotze, M. & Rybak, M.E. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. Cancer J. Sci. Am. 4, 46-51 (1998).
30. + T cells, analyzed at the single-cell level. J. Exp. Med. 184, 473-483 (1996).
31. Breit, S. et al. A strict requirement of interleukin-4 for interleukin-4 induction in antigen-stimulated human memory T cells. Eur. J. Immunol. 26, 1860-1865 (1996).
32. Racke, M.K. et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180, 1961-1966 (1994).
33. Loetscher, P. et al. CCR5 is characteristic of Th1 lymphocytes. Nature 391, 344-345 (1998).
34. Biedermann, T. et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J. Exp. Med. 192, 1441-1452 (2000).
35. Luftl, M., Degitz, K., DegiLz, K., Plewig, G. & Rocken, M. Psoralen bath plus UV-A therapy. Possibilities and limitations. Arch. Dermatol. 133, 1597-1603 (1997).
36. Blumberg, H. et al. Interleukin-20: Discovery, receptor identification and the role in epidermal function. Cell 104, 9-19 (2001).
37. Mazzucchelli, L. et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am. J. Pathol. 144, 997-1007 (1994).
38. Koch, A.E. et al. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum. 44, 31-40 (2001).
39. Nelms, K., Keegan, A.D., Zamorano, J. & Paul, W.E. The IL-4 receptor: Signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17, 701-738 (1999).
40. Rodriguez-Palmero, M., Hara, T., Thumbs, A. & Hunig, T. Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur J. Immunol. 29, 3914-3924 (1999).
41. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167-1175 (2000).
42. Kalinski, P. et al. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: Reversal of polarized Th2 phenotype by dendritic cells. J. Immunol. 165, 1877-1881 (2000).
43. Fickenscher, H. et al. The interleukin-10 family of cytokines. Trends Immunol. 23, 89-96 (2002).
44. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nature Med. 6, 1176-1182 (2000).
45. Leach, M.W., Rybak, M.E. & Rosenblum, I.Y. Safety evaluation of recombinant human interleukin-4. II. Clinical studies. Clin. Immunol. Immunopathol 83, 12-14 (1997).
46. Mack, M. et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nature Med. 6, 769-775 (2000).